Abstract
Alpha-actin-1 (ACTN1) is a cytoskeletal protein, and new evidence suggests that it is associated with tumor progression and prognosis. However, the expression of ACTN1 in thyroid carcinoma (THCA) and its biological functions are not fully understood. This study aimed to explore the expression and biological function of ACTN1 in THCA. Bioinformatics analysis revealed that ACTN1 was significantly upregulated in THCA and was associated with tumor size, extraglandular invasion, lymph node and distant metastasis, patient prognosis, and immune cell infiltration. qRT-PCR, immunohistochemistry, and western blotting verified the high expression of ACTN1 in the PTC samples. In vitro and in vivo experiments showed that overexpression of ACTN1 promoted THCA cell proliferation, cell cycle, migration, and invasion, and induced epithelial-mesenchymal transition (EMT); knockdown of ACTN1 inhibited these malignant behaviors. Mechanistically, ACTN1 knockdown reduced the phosphorylation levels of PI3K, AKT, and mTOR, whereas its overexpression increased these levels. After treating ACTN1 knockdown cells with the PI3K activator 740Y-P, the invasion and migration ability of the tumor was restored, suggesting that ACTN1 may promote the invasion and migration of THCA by activating the PI3K/AKT/mTOR pathway. In conclusion, ACTN1 is an important regulator of THCA progression and may serve as a potential molecular marker for predicting THCA invasion and metastasis.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-024-83719-3.
Keywords: Thyroid cancer, ACTN1, Tumour immunity, Epithelial‒mesenchymal transition (EMT), Tumour metastasis, Aggressive subtypes, Prognosis
Subject terms: Cancer, Computational biology and bioinformatics, Immunology, Oncology
Introduction
Thyroid carcinoma (THCA) is the most common malignant tumor of the endocrine system, and its incidence has increased worldwide in recent years1. Although the prognosis of THCA is generally good, some cases show malignant characteristics at an early stage, such as extraglandular invasion, vascular invasion, lymph node metastasis, and distant metastasis2,3. Moreover, these THCA tumors are insensitive to traditional treatments, such as surgery, postoperative 131I therapy, and TSH suppression therapy4. Therefore, early detection of relevant molecular pathological prognostic markers is crucial to accurately identify THCAs with aggressive malignant characteristics such as extraglandular invasion, vascular invasion, lymph node metastasis, and distant metastasis.
Alpha-actinins (ACTNs) are dimeric actin cross-linking proteins characterized by an N-terminal calponin homology domain and a C-terminal EF-hand motif, which are crucial for the cellular cytoskeletal architecture5. The alpha-actinin family primarily consists of four members: alpha-actinin-1 (ACTN1) and alpha-actinin-4 (ACTN4), which are expressed in non-muscle tissues, and alpha-actinin-2 (ACTN2) and alpha-actinin-3 (ACTN3), which are expressed in smooth muscle and the central nervous system6. It was originally believed that ACTN mediates muscle contraction by connecting adjacent sarcomere actin filaments in the muscle cells. However, recent studies have shown that ACTN1 and ACTN4 not only mediate muscle contraction, but also regulate the flexibility of actin filaments, form pseudopodia, affect cell adhesion and migration, and thus promote tumor invasion and metastasis7,8.
Extensive research has shown that the dysregulated expression of ACTN4 in various cancers, including thyroid, breast, cervical, and pancreatic cancers, affects cytoplasmic division, cell adhesion, and migration and promotes metastasis9–12. Conversely, homologous ACTN1, which is highly similar to ACTN4, has been relatively poorly studied in tumors. In recent years, it has been found that ACTN1 is associated with tumor progression and chemotherapy resistance and may be a potential target for tumor therapy13,14. For example, upregulation of ACTN1 in breast cancer disrupts E-cadherin adhesion, induces epithelial-mesenchymal transition (EMT), and contributes to cancer progression15,16. However, the biological function of ACTN1 in thyroid cancer remains unclear.
In this study, we aimed to clarify the expression and biological function of ACTN1 in THCA and explore the potential mechanism for promoting its progression. Through comprehensive bioinformatics analysis, we found that ACTN1 was upregulated in THCA and was closely related to extraglandular invasion and metastasis of tumors, genetic variation, and immune infiltration. Subsequently, combined with a series of in vitro and in vivo experiments, we found that ACTN1 may promote the progression of thyroid cancer by activating the PI3K/AKT/mTOR signaling pathway, suggesting that ACTN1 may be a potential diagnostic marker and therapeutic target for predicting the progression.
Materials and methods
Data collection and processing
The Cancer Genome Atlas (TCGA; http://cancergenome.nih.gov) and Genotype-Tissue Expression (GTEx; http://commonfund.nih.gov/GTEx/) databases were used to assess the differential expression of ACTN1 mRNA between normal and tumor tissues. The Human Protein Atlas (HPA; https://www.proteinatlas.org/) was used to examine ACTN1 protein expression in normal and pancancer tissues. ACTN1 expression in THCA was analyzed based on gene chip data and RNA-Seq data from the tnmplot database (https://tnmplot.com/analysis/)17. The subcellular localization of ACTN1 was predicted using the GeneCards portal (https://www.genecards.org/)18.
Clinicopathological characteristics and survival analysis
We analyzed the correlation between ACTN1 expression and the clinical features of THCA patients via the UALCAN online portal (http://ualcan.path.uab.edu/analysis.html) and the MEXPRESS online platform (https://www.mexpress.be/index.html)19,20. The impact of ACTN1 expression on the prognosis of THCA patients was assessed using the Kaplan-Meier plotter database (https://kmplot.com/analysis/index)21.
Gene set enrichment analyses
Using “TCGA_THCA” cohort data from the LinkedOmics database (http://www.linkedomics.org/login.php), we identified genes co-expressed with ACTN1. The co-expressed genes were subjected to KEGG enrichment analyses via the “LinkInterpreter” module to explore potential pathways through which ACTN1 exerts its function22.
Immune infiltration analysis
The TIMER database (http://timer.cistrome.org/) is an online platform that includes comprehensive tumor immune infiltration data. The “Gene” and “Gene_Mutation” modules of the website were utilized to assess the correlation between ACTN1 expression and immune cell infiltration in THCA23. The TISIDB online database (http://cis.hku.hk/TISIDB/index.php) was used to analyze the interactions between tumors and the immune system. Using this platform, we investigated the relationship between the expression of ACTN1 and expression of immunoinhibitors, immunostimulators, MHC molecules, chemokines, and receptors24. SangerBox (http://vip.sangerbox.com/home.html) is an online portal for TCGA data analysis25. Using the “immune infiltration” analysis module of this website, we examined the correlation of ACTN1 with the stromal score, immune score, and ESTIMATE score in THCA patients. Finally, by integrating data from the TIMER and SangerBox databases, we conducted a comprehensive analysis of the mutational landscape of ACTN1 in THCA, and assessed the correlation between ACTN1 expression and mutations commonly associated with TCHA (BRAF, TG, HRAS, and NRAS gene mutations).
PPI and molecular docking
GeneMANIA (http://genemania.org/), STRING (https://string-db.org/), and GPS-Prot (http://gpsprot.org/) are classic databases for analyzing PPI. Using these three databases, we constructed a PPI network for ACTN126–28. Molecular docking was used to validate the binding activities between proteins. The protein IDs for ACTN1, PDLIM1, ACTN4, and CTNNA1 were retrieved from the UniProt online database (https://www.uniprot.org/) as P12814, O00151, O43707, and P35221, respectively29. Subsequently, molecular docking between ACTN1 and the PDLIM1, ACTN4, and CTNNA1 proteins was performed using the HDOCK online platform (http://hdock.phys.hust.edu.cn/)30. Finally, PyMOL (version 4.3.0) and Ligplus software were used to visualize the three-dimensional amino acid residue interactions among these four proteins.
Patient tissue samples and immunohistochemistry (IHC)
Considering that PTC is the most common type of thyroid cancer, we collected tissue samples from 59 patients with postoperative pathological diagnosis of PTC in the Affiliated Hospital of Guizhou Medical University for experimental verification. All participants, human data, and tissues were collected after obtaining informed consent, and all methods followed the principles of the Declaration of Helsinki and obtained ethical approval from the Institutional Ethics Committee of Guizhou Medical University (approval number: 2023 (680)). The IHC procedures involved dehydration, paraffin embedding, slicing into 4 μm sections, deparaffinization in xylene, and antigen retrieval with EDTA. Endogenous peroxidase activity was blocked with H2O2, followed by blocking with 5% BSA. The sections were incubated with primary antibodies overnight at 4 °C, washed with PBS, and incubated with secondary antibodies at room temperature for 1 h. The immunohistochemical reaction was visualized via diaminobenzidine, followed by ethanol dehydration, mounting with resin, microscopic examination, and assessment of ACTN1 expression based on the staining intensity and percentage of positive cells.
Cell culture
Human thyroid follicular epithelial cells (Nthy-ori3-1) and human THCA cells (TPC-1 and KTC-1) were purchased from Pricella (Wuhan, China). Human THCA cell lines (BCPAP and K1) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Nthy-ori3-1, B-CPAP, KTC-1, and TPC-1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, whereas K1 cells were cultured in DMEM supplemented with 10% fetal bovine serum. The cells were maintained in a humidified incubator at 37 °C and 5% CO2.
Western blot analysis
Protein extraction from THCA tissues and cells was performed using RIPA buffer (Solarbio, Beijing, China) supplemented with protease and phosphatase inhibitors. After ultrasonic disruption, the samples were incubated on ice for 30 min, followed by centrifugation to collect the supernatants. Protein concentration was determined using a BCA protein assay kit (Beyotime, Shanghai, China). The protein lysate (30 µg) was subjected to 10% SDS-PAGE and transferred to a PVDF membrane, which was blocked with 5% skim milk powder and incubated with primary antibodies at 4 °C overnight. Finally, TBST-washed membranes were incubated with secondary antibodies, and the proteins were visualized using an ECL kit (Bergolin Biotechnology, Liaoning, China). ImageJ software was used to analyze the grayscale values of the images. Details of the primary antibodies and internal controls used are provided in Supplementary Table 1.
qRT‒PCR
Acquiring total RNA using the TRIzol reagent kit (Invitrogen, USA), cDNA synthesis and real-time fluorescence quantitative PCR were performed using a cDNA reverse transcription kit(Yeasen, Shanghai, China) and Hieff UNICON® Universal Blue qPCR SYBR Green Master Mix (Yeasen, Shanghai, China). The primer sequences for the target and reference genes are provided in Supplementary Table 2.
Plasmid construction and infection
To achieve gene knockdown or overexpression of ACTN1, stable transduction was performed using lentiviral vectors containing a specific shRNA (GenePharma, Shanghai, China). KTC-1 and PTC-1 cells, which showed the most significant upregulation of ACTN1 expression, were seeded in 6-well plates, and an empty lentiviral vector was used as a negative control. When the cell confluence reached approximately 40–60%, each well was supplemented with 1 ml of complete medium containing lentivirus at a multiplicity of infection (MOI) of 20 and incubated for 96 h, and the transfection efficiency of the THCA cells (indicated by fluorescence) was assessed via fluorescence microscopy. The transfected cells were then selected with 2 µg/ml puromycin to establish stable cell lines. Finally, the efficiency of ACTN1 knockdown or overexpression was evaluated by western blotting. Specific ACTN1 short hairpin RNA (shRNA) sequences are provided in Supplementary Table 3.
Cell proliferation assay
THCA cells were inoculated at 4 × 103 cells per well in 96-well plates. After 0, 24, 48, 72, and 96 h, CCK8 reagent was added and incubated at 37 °C for 2 h. Absorbance was measured at 450 nm using a microplate reader to determine the OD values of each well.
Colony formation assay
THCA cells (1 × 103) were seeded in 6-well plates. The cells were cultured in 10% fetal bovine serum medium for 14 days. After washing three times with PBS, the cells were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet for 20 min. Images were captured, and the colonies were counted.
Cell cycle detection by flow cytometry
Cell cycle analysis was performed according to the manufacturer’s instructions (KGA9101; KeyGEN Biotech). After the collection of THCA cells, the cells were centrifuged (2000 rpm for 5 min), and the supernatant was discarded. The cells were fixed overnight with 70% pre-cooled ethanol. Before analysis, the samples were centrifuged (3000 rpm for 3 min), washed once with PBS under the same centrifugation conditions, and incubated at room temperature in 500 µL of PI/RNase A working solution (PI: RNase A = 9:1) for 30–60 min in the dark. G1-, S-, and G2-phase cells were collected via a Navios flow cytometer (Beckman Coulter, USA), and the data were analysed via FlowJo (version 10.8.1).
Migration and invasion assays
Transwell chambers (Corning, NY, USA) with or without matrix gel coating were prepared in 24-well plates. Subsequently, 4 × 104 THCA cells were seeded in serum-free medium in the upper chamber and 500 µl of 20% fetal bovine serum 1640 medium was added to the lower chamber. The cells were incubated at 37 °C for 24 (migration) or 48 h (invasion). The cells remaining in the upper chamber were removed using a cotton swab, and the cells that passed through the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Images were captured under a microscope and the number of migrated or invaded cells was counted.
Wound healing assay
Transfected KTC-1 and TPC-1 cells were evenly plated in 6-well plates. When the cells reached 100% confluence per well, a straight line was scratched across the wells using the tip of a 200 µl pipette. After washing with PBS, the serum-free medium was replaced and the cells were incubated in a standard culture incubator. The migratory ability of the cells was observed and photographed at 0 and 24 h using a microscope.
RNA sequencing analysis
After extracting mRNA from the KTC-1 cell line, SeqHealth Technology Co., LTD (Wuhan, China) was commissioned to perform whole-transcriptome sequencing. sh-NC and sh-ACTN1 were used as the control and experimental groups, respectively. Differential expression analysis was performed using the edgeR package (version 3.12.1), and the significantly differentially expressed genes between the control and experimental groups were identified using FDR ≤ 0.05 and |log2FC| ≥ 1 as the screening criteria. Finally, KOBAS software (version 2.1.1) was used for gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to clarify the biological significance and regulatory mechanisms of differentially expressed genes.
Nude mouse subcutaneous tumor formation experiment
BALB/C nude mice (4–5 weeks old, male) were provided by Sichuan Weitonglihua Experimental Animal Technology Co., Ltd., with animal production license number: SCXK(Sichuan)2023-0040. Twenty BALB/C nude mice were randomly divided into four groups: vector, ACTN1, sh-control, and sh-ACTN1#1, with five mice per group. Subsequently, 1.2 × 107 TPC-1 cells transfected with ACTN1 were subcutaneously inoculated into the right axilla of mice. Tumor size was measured every six days. After 30 days, all mice were deeply anesthetized with isoflurane and then executed by cervical dislocation. Every animal experiment was approved by the Animal Care and Welfare Committee of the Affiliated Hospital of Guizhou Medical University (ethics number No. 2305046) and was conducted in accordance with the ARRIVE guidelines related to animal handling.
Statistical analysis
All data of these experiments were analyzed using SPSS 22.0, and GraphPad Prism 8.The Wilcoxon test or paired t-tes t was used for two-group comparisons, whereas ANOVA was used for multiple-group comparisons. Statistical significance was set at P < 0.05, and is denoted as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. All experiments were conducted in triplicate.
Results
Expression and localization of ACTN1 in normal and pancancer tissues
At the mRNA level, ACTN1 is expressed at relatively high levels in tissues such as smooth muscle and seminal vesicles and at relatively low levels in tissues such as parathyroid glands and skeletal muscle (Fig. 1A). In pancancer tissues, ACTN1 mRNA is significantly upregulated in various tumors, including THCA (Fig. 1B). At the protein level, ACTN1 is abundantly expressed in organs such as the cerebral cortex and hippocampus but is poorly expressed in tissues such as the esophagus and soft tissue (Fig. 1C). In pancancer tissues, ACTN1 is expressed at higher levels in tumors such as THCA and colorectal cancer, whereas it is expressed at lower levels in tumors such as glioma and renal cancer (Fig. 1D). Finally, the GeneCards database was used to predict the cellular localization of ACTN1, primarily in the cytosol and cytoskeleton (Fig. 1E).
Fig. 1.
Expression and subcellular localisation of ACTN1 in normal human and pancancer tissues. (A,B) mRNA expression of ACTN1 in normal and pancancer tissues. (C,D) Protein expression of ACTN1 in normal and pancancer tissues. (E) Subcellular localization of ACTN1.
ACTN1 overexpression in THCA
We verified whether the expression of ACTN1 in thyroid cancer was consistent with pan-cancer analysis. RNA-seq and gene chip data from the TNMplot database, along with IHC staining data from the HPA database, were utilized to analyze ACTN1 expression in THCA. The results demonstrated increased mRNA and protein expression of ACTN1 in THCA (Fig. 2A-C). Subsequently, qRT-PCR experiments were performed on 59 PTC clinical samples, confirming that ACTN1 mRNA expression was significantly upregulated in cancer tissues (Fig. 2D). Additionally, Western blotting and IHC experiments confirmed increased ACTN1 protein expression in PTC tissues (Fig. 2E, F). Finally, differences in ACTN1 expression in THCA cells and normal thyroid follicular epithelial cells were examined, and it was found that ACTN1 expression was also significantly elevated in THCA cells (Fig. 2G, H). This suggests that ACTN1 is overexpressed in THCA and may play an oncogenic role in the progression.
Fig. 2.
ACTN1 expression in THCA tissue and cells. (A,B) ACTN1 RNA-seq data and gene chip data from the TNMplot database. (C) Representative IHC images of ACTN1 obtained from HPA database. (D,E) ACTN1 expression in PTC and adjacent normal tissues. (F) Representative images of immunohistochemical analysis of ACTN1 in anaplastic thyroid carcinoma (Case 1) and papillary thyroid carcinoma (Case 2) from clinical samples. (G,H) ACTN1 expression in THCA cell lines and normal thyroid follicular epithelial cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Correlation of ACTN1 with clinicopathological features and prognosis in PTC patients
Subsequently, the impact of ACTN1 expression on clinicopathological features and prognosis was analyzed. The UALCAN database findings revealed higher ACTN1 expression in THCA patients with lymph node metastasis, advanced tumor stage, and high-risk subtypes, whereas patients without these pathological features presented lower ACTN1 expression (Fig. S1A-C). Analysis via the MEXPRESS website also revealed significant differences in ACTN1 expression between patients grouped according to extraglandular invasion status, lymph node metastasis count, and distant metastasis status; however, there were no statistically significant differences in patients grouped according to age, sex, or tumor size (Fig. S1D). Furthermore, we categorized the 59 PTC patients into high expression group (n = 42) and low-expression groups (n = 17) according to the median ACTN1 mRNA expression level. The relationship between ACTN1 expression and clinicopathological parameters was explored. As illustrated in Table 1, ACTN1 expression levels were significantly correlated with tumor size (p = 0.024), extraglandular invasion (p = 0.01), lymph node metastasis (p = 0.047), and distant metastasis (p = 0.037), whereas no correlation was observed with parameters such as age, sex, pTNM stage, or tumor number. Finally, using the Kaplan–Meier plotter database, the influence of ACTN1 expression on the prognosis of THCA was analyzed. The results revealed a statistically significant difference in the overall survival (OS) of THCA patients in the different ACTN1 expression groups, whereas disease-free survival (DFS) did not differ between the groups (Fig. S1E,F). These findings suggested that ACTN1 expression in THCA is associated with disease progression and prognosis.
Table 1.
A comparison of ACTN1 expression and the clinicopathological characteristics of PTC patients (chi-square test).
| Clinicopathological features | Number of patients (%) | ACTN1 expression level | X2 | P value | |
|---|---|---|---|---|---|
| Low | High | ||||
| Total cases | 59 | 17 | 42 | ||
| Age | 0.288 | 0.592 | |||
| ≤ 55 | 31 (52.5%) | 8 | 23 | ||
| > 55 | 28 (47.5%) | 9 | 19 | ||
| Sex | 0.046 | 0.831 | |||
| Female | 44 (74.6%) | 13 | 31 | ||
| Male | 15 (25.4%) | 4 | 11 | ||
| Tumour size | 5.124 | 0.024 | |||
| ≤ 2 | 28 (47.5%) | 12 | 16 | ||
| > 2 | 31 (52.5%) | 5 | 26 | ||
| pTNM stage | 0.017 | 0.744 | |||
| I–II | 47 (80.0%) | 14 | 33 | ||
| III–IV | 12 (20.0%) | 3 | 9 | ||
| Extraglandular invasion | 6.621 | 0.01 | |||
| No | 30 (51.0%) | 12 | 18 | ||
| Yes | 29 (49.0%) | 5 | 24 | ||
| Lymph node metastasis | 3.952 | 0.047 | |||
| N0 | 23 (39.0%) | 10 | 13 | ||
| N1 | 36 (61.0%) | 7 | 29 | ||
| Distant metastasis | 4.348 | 0.037 | |||
| M0 | 53 (90.0%) | 17 | 36 | ||
| M1 | 6 (10.0%) | 0 | 6 | ||
| Tumour number | 0.202 | 0.653 | |||
| Single | 32 (54.2%) | 10 | 22 | ||
| Multiple | 27 (45.8%) | 7 | 20 | ||
Bold values indicate P < 0.05.
Relationship between ACTN1 expression and the levels of tumour-infiltrating lymphocytes (TILs)
Tumor-infiltrating lymphocytes are pivotal effectors of tumor immunity, and studies have indicated their association with the progression and prognosis of THCA31,32. Therefore, the relationship between ACTN1 and tumor-infiltrating lymphocytes in patients with THCA was investigated. Analysis using the quanTIseq algorithm revealed that ACTN1 was associated with the levels of B cells, M1 macrophages, M2 macrophages, monocytes, neutrophils, NK cells, CD4 T cells, Tregs, and dendritic cells in THCA but not in CD8 T cells (Fig. 3A). The ESTIMATE algorithm results revealed that ACTN1 was positively correlated with the stromal score (r = 0.39, P = 4.1e-20), immune score (r = 0.22, P = 3.5e-7), and ESTIMATE score (r = 0.31, P = 1.1e-12) in the THCA cohort (Fig. 3B-D). The TIMER database results revealed that ACTN1 was positively correlated with the levels of B cells (r = 0.696, P = 4.26e-71), CD4 + T cells (r = 0.598, P = 1.25e-48), macrophages (r = 0.534, P = 2.81e-37), neutrophils (r = 0.659, P = 4.01e-62), and dendritic cells (r = 0.622, P = 2.82e-53), and negatively correlated with tumor purity (r = − 0.135, P = 2.78e-03) and the levels of CD8 + T cells (r = -0.142, P = 1.65e-03) (Fig. 3E). Finally, the relationship between ACTN1 copy number variation (CNV) and tumor-infiltrating lymphocyte immune cell infiltration levels was explored. The results indicated that ACTN1 CNV was associated with the levels of B cells, CD8 + T cells, CD4 + T cells, macrophages, neutrophils, and dendritic cells (Fig. 3F). These findings suggest that ACTN1 may influence immune cell responses during the development.
Fig. 3.
Relationship between ACTN1 and tumour-infiltrating lymphocytes. (A) The quanTIseq algorithm was used to analyze the effects of ACTN1 and tumor-infiltrating lymphocytes. (B–D) ESTIMATE algorithm analysis of the impact of ACTN1 on the stromal score, immune score, and ESTIMATE score. (E) Analysis of the correlation between ACTN1 and tumor purity using the TIMER database. (F) Correlation between ACTN1 CNV and tumour-infiltrating lymphocytes. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
ACTN1 expression is associated with immunomodulators and chemokines
Immunotherapy has changed the treatment of cancer, and the expression of immune checkpoint genes is closely related to the efficacy of immunotherapy. Therefore, we used the TISIDB database to analyze the relationship between ACTN1 expression and expression of immune regulators and chemokines. The results revealed significant associations between ACTN1 expression and the expression of multiple immunomodulators and chemokines (P < 2.2e-16). For example, ACTN1 was positively correlated with immune stimulatory factors such as CD276 (Spearman: rho = 0.668), TNFSF9 (Spearman: rho = 0.585), CD70 (Spearman: rho = 0.561), and TNFSF18 (Spearman: rho = 0.559) (Fig. 4A, B). It was also positively correlated with immune inhibitory factors, including TGFBR1 (Spearman: rho = 0.539), VTCN1 (Spearman: rho = 0.524), CTLA4 (Spearman: rho = 0.429), and CD274 (Spearman: rho = 0.426) (Fig. 4C, D). Strong correlations were observed between ACTN1 and MHC molecules such as HLA-DRA (Spearman: rho = 0.473), HLA-DOA (Spearman: rho = 0.459), HLA-G (Spearman: rho = 0.456), and HLA-DRB1 (Spearman: rho = 0.417) (Fig. 4E, F). Finally, correlations between ACTN1 expression and the expression of chemokines and their receptors were analyzed. ACTN1 expression was positively correlated with the expression of chemokines such as CXCL16 (Spearman: rho = 0.602), CXCL5 (Spearman: rho = 0.6), CXCL8 (Spearman: rho = 0.587), and CCL13 (Spearman: rho = 0.581) (Fig. S2A, B), and with chemokine receptors, including CCR1 (Spearman: rho = 0.504), CCR8 (Spearman: rho = 0.473), CCR4 (Spearman: rho = 0.471), and CCR6 (Spearman: rho = 0.447) (Fig. S2C, D). These results suggest that ACTN1 regulates tumor immune responses and participates in tumor progression by interacting with immunomodulators and chemokines.
Fig. 4.
Correlation between ACTN1 and immunomodulators in THCA. (A,B) Correlation between ACTN1 and immunostimulatory factor expression. (C,D) Correlation between ACTN1 and immunoinhibitory factor expression. (D,E) Correlation between ACTN1 expression and MHC molecule expression.
Analysis of ACTN1 expression and mutation status
Extensive research has shown that the development and progression are closely related to point mutations and epigenetic modifications in various genes, including BRAF and RAS. Targeted therapies that focus on gene mutations play an irreplaceable role in THCA33. Therefore, this study analyzed the mutation landscape associated with ACTN1 expression in THCA patients. The results revealed that the mutation type most closely associated with differential ACTN1 expression in THCA was missense mutation, and the most commonly mutated genes were BRAF, NRAS, TG, and HRAS (Fig. 5A). ACTN1 expression was upregulated in tumor specimens with BRAF mutations, whereas it was downregulated in tumor specimens with NRAS, TG, and HRAS mutations (Fig. 5B-E). In addition, the effects of BRAF, NRAS, TG, and HRAS mutations on immune cell infiltration were examined. The results indicated that in BRAF-mutant THCA, the infiltration levels of five immune cell types (B cells, CD4 + T cells, macrophages, neutrophils, and dendritic cells) were significantly increased (Fig. 5F). Conversely, in THCA patients with NRAS, TG, and HRAS mutations, the infiltration levels of four immune cell types (CD4 + T cells, macrophages, neutrophils, and dendritic cells) were significantly decreased (Fig. 5G–I).
Fig. 5.
Analysis of the ACTN1 mutation landscape. (A) Mutation types and genes associated with high and low ACTN1 expression in THCA. (B–E) Relationship between ACTN1 expression and BRAF, NRAS, TG, and HRAS gene mutations. (F–I) Correlation between BRAF, NRAS, TG, and HRAS mutations and infiltrating immune cells in THCA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
PPI and molecular docking of ACTN1
The PPI network of ACTN1 was constructed using STRING, GeneMANIA, and GPS-Prot databases. The results indicated that PDZ and LIM domain protein 1 (PDLIM1), catenin alpha 1 (CTNNA1), and ACTN4 may interact with ACTN1 (Fig. 6A–D). The expression levels of PDLIM1, CTNNA1, and ACTN4 in THCA and their correlation with ACTN1 expression levels were analyzed. PDLIM1, CTNNA1, and ACTN4 expression was upregulated in cancer tissues compared to adjacent normal tissues and was positively correlated with ACTN1 expression (Fig. 6E–J). Finally, molecular docking was performed to validate the binding between ACTN1 and PDLIM1, CTNNA1, or ACTN4. The results revealed that the binding scores for ACTN1 with PDLIM1, CTNNA1, and ACTN4 were − 282.05 (confidence score 93%), − 223.16 (confidence score 89%), and − 254.95 (confidence score 81%), respectively (Fig. 6K–M).
Fig. 6.
Interacting proteins and molecular docking of ACTN1. (A–D) The PPI network was constructed using the STRING, GeneMANIA, and GPS-Prot databases. (E–G) Expression of PDLIM1, CTNNA1, and ACTN4 in THCA cells. (H–J) Correlation of ACTN1 expression with PDLIM1, CTNNA1, and ACTN4 expression in 502 THCA patients. (K–M) Three-dimensional molecular docking of ACTN1 with PDLIM1, CTNNA1, and ACTN4. The green ribbon structure represents the ACTN1 protein, blue ribbon structure represents the PDLIM1 protein, brown ribbon structure represents the CTNNA1 protein, and purple ribbon structure represents the ACTN4 protein. Stick structures represent interacting amino acid residues, yellow dashed lines represent hydrogen bonds, and blue dashed lines represent salt-bridge interactions.
ACTN1 promotes the proliferation of THCA cells
To validate the function of ACTN1 in THCA cells, KTC-1 and TPC-1 cells with the most pronounced upregulation in ACTN1 expression were selected for functional validation. Stable lentiviral vectors were established to knock down and overexpress ACTN1, along with control cell lines, and the transfection efficiency was verified by western blotting (Fig. 7A, B). The effects of interference with ACTN1 expression on cell proliferation and cell cycle were subsequently assessed using the CCK-8 assay, colony formation assay, and flow cytometry. The results of the CCK-8 assay demonstrated decreased cell viability following ACTN1 knockdown and significantly increased viability after ACTN1 overexpression in THCA cells (Fig. 7C–F). Colony formation experiments also indicated that downregulation of ACTN1 decreased cell proliferation capacity, whereas overexpression of ACTN1 promoted proliferation (Fig. 7G, H). Flow cytometry revealed that ACTN1 knockdown inhibited cell cycle progression in THCA cells, whereas ACTN1 overexpression accelerated cell cycle progression (Fig. 7I–N). These data indicated that ACTN1 is involved in regulating the proliferation and cell cycle of THCA cells, thereby promoting THCA progression.
Fig. 7.
Verification of ACTN1 transfection efficiency and effect on THCA cell proliferation. (A,B) Verification of transfection efficiency of knockdown or overexpression of ACTN1. (C–F) CCK8 assay verifies the effect of ACTN1 knockdown or overexpression on the proliferation of KTC-1 and TPC-1 cells. (G,H) Colony formation assay was used to verify the effect of ACTN1 on cell proliferation. (I–N) Flow cytometry experiments to verify the effect of ACTN1 on the cell cycle. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
ACTN1 promotes the invasion, migration, and EMT of THCA cells
Based on the analysis of the clinical characteristics, ACTN1 expression was found to be associated with extraglandular invasion, lymph node metastasis, and distant metastasis in THCA. Therefore, we performed basic experiments to determine the relationship between ACTN1 expression and THCA cell migration and invasion. Transwell assays demonstrated reduced migration and invasion capabilities of THCA cells following ACTN1 knockdown, whereas overexpression of ACTN1 enhanced cell migration and invasion (Fig. 8A–D). Wound healing assays also revealed smaller wound closure areas and decreased migration rates in the ACTN1 knockdown group, whereas the ACTN1 overexpression group presented larger wound closure areas and increased migration rates (Fig. 8E–H). Furthermore, considering that the role of ACTN1 as a cytoskeletal protein is closely associated with cell motility and that epithelial‒mesenchymal transition (EMT) is a key mechanism promoting tumor cell motility34, we analyzed the effect of ACTN1 on EMT. Western blot analysis revealed that ACTN1 knockdown decreased the expression of N-cadherin, vimentin, and Snail, and increased the expression of E-cadherin. Conversely, overexpression of ACTN1 increased the expression of N-cadherin, vimentin, and Snail, and decreased the expression of E-cadherin (Fig. 8I–L). These data indicated that the inhibition of ACTN1 expression significantly suppressed cell invasion, migration, and EMT.
Fig. 8.
ACTN1 promotes migration, invasion, and EMT in THCA. (A–D) Transwell assay was used to evaluate the effect of ACTN1 on the migration and invasion of THCA cells. (E–H) Wound healing assay was used to evaluate the effect of ACTN1 on THCA cell migration. (I–L) Western blotting analysis of the effect of ACTN1 on EMT. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
ACTN1 promotes thyroid cancer progression by activating the PI3K/AKT/mTOR signaling pathway
In this study, transcriptome sequencing was performed on KTC-1 cells in the ACTN1 knockdown group and the control group, and 1770 upregulated genes and 404 downregulated genes were identified (Fig. 9A). GO enrichment analysis showed that the differentially expressed genes were mainly involved in cell binding and activation (biological process), nucleus and cytoplasm (cellular components), cell metabolism and translation (molecular function), etc. (Fig. 9B). KEGG analysis showed that these genes were significantly enriched in the PI3K-Akt pathway (Fig. 9C). In addition, genes co-expressed with ACTN1 in the TCGA-THCA cohort were also enriched in the PI3K/AKT pathway (Fig. S3A, B), so it is speculated that ACTN1 promotes the progression of thyroid cancer by regulating the PI3K/AKT pathway. Experimental verification showed that ACTN1 knockdown reduced the phosphorylation levels of PI3K, AKT, and mTOR, while overexpression increased the phosphorylation of these molecules (Fig. 9D–K). After the knockdown cells were treated with the PI3K activator 740Y-P, the cell migration ability was restored (Fig. S4A–D), and the Transwell experiment showed that 740Y-P could reduce the effect of knockdown of ACTN1 on cell invasion (Fig. S4E–J). In summary, ACTN1 may promote the invasion and migration of THCA by activating the PI3K/AKT/mTOR pathway.
Fig. 9.
ACTN1 regulates the PI3K/AKT/mTOR pathway in THCA cells. (A) Transcriptome sequencing of ACTN1 knocked-down KTC-1 cells, showing the volcano plot of differentially expressed genes (DEGs); (B) GO functional enrichment analysis of DEGs, including enrichment results of biological process (BP), cellular component (CC), and molecular function (MF); (C) KEGG functional enrichment analysis of DEGs, screened biological pathways; (D–G) Effects of ACTN1 knockdown or overexpression on the relative expression levels of PI3K, AKT, mTOR, and their phosphorylated forms (p-PI3K, p-AKT, p-mTOR) in KTC-1 cells; (H-K) Effects of ACTN1 knockdown or overexpression on the relative expression levels of PI3K, AKT, mTOR, and their phosphorylated forms (p-PI3K, p-AKT, p-mTOR) in TPC-1 cells.
ACTN1 promotes tumor growth in nude mice
Subcutaneous tumor formation experiments in nude mice were performed by stably transfecting TPC-1 cells with ACTN1. The results showed that cells overexpressing ACTN1 had larger tumor volume and weight in nude mice and a faster growth rate; knockdown of ACTN1 resulted in reduced tumor volume and weight and a slower growth rate (Fig. 10A–C). HE staining showed that the tumor cells in the four groups were irregular in morphology and had darker nuclear staining, which was particularly obvious in the overexpression group and relatively less in the knockdown group (Fig. 10D). Immunohistochemistry showed that the expression levels of ACTN1 and Ki67 in tumors overexpressing ACTN1 were higher than those in the control group, whereas the expression levels of these two proteins in the knockdown group were significantly reduced (Fig. 10E). In summary, ACTN1 expression is significantly associated with the growth of thyroid cancer cells.
Fig. 10.
ACTN1 promotes tumor growth in nude mice. (A) Representative images of subcutaneous tumors in each group: ACTN1, Vector, shNC, sh-ACTN1#1; (B) Volume of subcutaneous tumors in each group: ACTN1, Vector, shNC, sh-ACTN1#1; (C) Weight of subcutaneous tumors in each group: ACTN1, Vector, shNC, sh-ACTN1#1; (D) HE staining of subcutaneous tumors in each group: ACTN1, Vector, shNC, sh-ACTN1#1; (E) Immunohistochemical analysis of ACTN1 and Ki67 in subcutaneous tumors in each group: ACTN1, Vector, shNC, sh-ACTN1#1.
Discussion
In recent decades, the incidence of various tumors, including THCA, has increased significantly. According to the 2020 Global Cancer Statistics report, there were 586,202 new cases of THCA globally, accounting for 95% of all endocrine system cancer cases35. Most patients with thyroid cancer have a good survival rate after surgery and radioactive iodine treatment; however, the treatment effect on thyroid cancer with recurrence, metastasis, and invasive subtypes is not optimistic36. Fortunately, in recent years, advancements in technologies such as microarrays and sequencing have enabled the use of bioinformatics analyses to explore potential diagnostic and prognostic biomarkers and predict therapeutic targets for cancer, providing new insights into cancer diagnosis and treatment37. In this study, we analyzed the mRNA and protein expression profiles of ACTN1 using a comprehensive bioinformatics approach and found that ACTN1 expression was upregulated in various tumor tissues, including THCA. The correlation between ACTN1 expression and the clinicopathological characteristics and prognosis of THCA patients was further explored, and the results showed that increased ACTN1 expression was closely related to advanced tumor stage, extraglandular invasion, lymph node metastasis, and distant metastasis and affected the prognosis of THCA. Furthermore, we collected clinicopathological data for patients with PTC for experimental validation and demonstrated that elevated ACTN1 expression in cancer tissues is closely associated with tumor size, extraglandular invasion, lymph node metastasis, and distant metastasis.
The tumor microenvironment is a complex system consisting of multiple cell types and signaling molecules that affect cancer prognosis. Immune cells, in particular, play a key role in invasion and metastasis38,39. Using the quanTIseq, ESTIMATE, and TIMER databases, we found that ACTN1 expression was positively correlated with the levels of B cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in THCA and negatively correlated with tumor purity and CD8+ T cell levels, and its copy number variation was associated with the infiltration levels of these immune cells. Immune checkpoint inhibitors, such as CTLA-4 and PD-L1, are widely used in tumor immunotherapy40. For example, PD-1 inhibitors combined with tyrosine kinase inhibitors can prolong the survival of patients with poorly differentiated thyroid cancer41. This study showed that ACTN1 was associated with the expression of immunosuppressive factors (such as PD-L1 and CTLA4), immunostimulatory factors (CD276 and TNFSF9), chemokines (CXCL16 and CXCL5) and their receptors (CCR1 and CCR8), suggesting that ACTN1 is involved in THCA progression by regulating tumor immune response.In addition, BRAF mutations have been reported to be associated with the THCA immune microenvironment, manifested by upregulation of PD-L1 and CTLA-4 and downregulation of tumor-specific major histocompatibility complex42. This study found that immune cell infiltration was higher in samples with BRAF mutations but lower in samples with NRAS, TG, and HRAS mutations.
Guo et al. reported that elevated expression of ACTN1 is correlated with a poor prognosis in oral cancer patients and that silencing ACTN1 inhibits the proliferation of oral squamous cell carcinoma cells43. In vitro experiments in this study showed that ACTN1 knockdown inhibited KTC-1 and TPC-1 cell proliferation, whereas overexpression increased cell viability. In vivo experiments showed that tumors in the ACTN1 overexpression group grew faster, were larger, and heavier in weight, suggesting that ACTN1 plays an important role in regulating cell proliferation and tumor growth. Invasion and metastasis are the main causes of cancer death44. ACTN1 interacts with LLGL2 to damage actin filaments, thereby affecting the invasion and metastasis of ovarian cancer cells45. The present study showed that ACTN1 knockdown inhibited the migration and invasion of KTC-1 and TPC-1 cells, whereas overexpression promoted these processes. EMT is the mechanism of tumor invasion and metastasis46. For example, ACTN1 induces EMT in gastric cancer cells via the AKT/GSK3β/β-catenin pathway47. Our results indicated that ACTN1 knockdown increased the expression of the epithelial marker E-cadherin while suppressing the expression of the mesenchymal markers N-cadherin, vimentin, and Snail. The opposite effects were observed with ACTN1 overexpression. In summary, ACTN1 plays an oncogenic role in thyroid cancer and promotes tumor migration, invasion, and EMT.
The PI3K/AKT/mTOR signaling pathway enhances the metastatic potential of tumor cells by promoting their survival, proliferation, and migration48. In this study, transcriptome sequencing of KTC-1 cells after ACTN1 knockdown and KEGG enrichment analysis of ACTN1 co-expressed genes in the TCGA-THCA cohort revealed that the PI3K/AKT signaling pathway was significantly enriched, suggesting that ACTN1, as a key regulator of the PI3K/AKT/mTOR pathway, is involved in thyroid cancer progression and metastasis. Experimental verification showed that ACTN1 knockdown significantly reduced the expression of PI3K, AKT, and mTOR phosphorylated proteins, whereas overexpression increased their expression. In addition, the PI3K activator 740Y-P reversed the decrease in cell invasion and migration caused by ACTN1 knockdown. These results indicated that ACTN1 affects the invasion and migration of thyroid cancer cells through the PI3K/AKT/mTOR pathway, revealing its mechanism of action and providing a theoretical basis for therapeutic strategies targeting this signaling pathway.
In summary, this study found that ACTN1 was associated with extrathyroidal spread, lymph node metastasis, distant metastasis, prognosis, and immune cell infiltration in patients with THCA. Mechanistically, ACTN1 may promote cancer cell migration and invasion by activating the PI3K/AKT/mTOR signaling pathway. However, the current study did not verify the effect of ACTN1 on immunity against thyroid cancer. In the future, we will explore the mechanism of action of ACTN1 in the immune microenvironment of thyroid cancer using immune experiments.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Acknowledgements
We thank all patients involved in this study and the Clinical Medical Research Center of Guizhou Medical University Affiliated Hospital for providing experimental platform support.
Author contributions
SC, XL, and WTW performed the experiments, data collection, analysis, and manuscript writing. XHC, NM, XYZ, and TZ performed the clinical data collection, participated in the discussion on selecting the research topic and scope, and edited the manuscript. QJG and DWZ conceived, designed, and supervised the study, and reviewed the manuscript. All authors have read and approved the final version of the manuscript.
Funding
This study was supported by the National Natural Science Foundation of China (81860478) and the Science and Technology Foundation of the Guizhou Health Commission (gzwkj2024-021).
Data availability
The data supporting the findings of this study are available from the corresponding author upon reasonable request. For more information or to request data, please contact the author at zzhaodaiwei@hotmail.com. The datasets used for the bioinformatics analysis in this study are public and can be found in the following databases: The Cancer Genome Atlas (https://cancergenome.nih.gov), Genotype Tissue Expression Database (https://commonfund.nih.gov/GTEx/data), Human Protein Atlas (https://www.proteinatlas.org/), tnmplot (https://tnmplot.com/analysis/), GeneCards (https://www.genecards.org/), UALCAN (http://ualcan.path.uab.edu/analysis.html), MEXPRESS (https://www.mexpress.be/index.html), Kaplan-Meier (https://kmplot.com/analysis/index), LinkedOmics (http://www.linkedomics.org/login.php), TIMER (http://timer.cistrome.org/), TISIDB (http://cis.hku.hk/TISIDB/index.php), SangerBox (http://vip.sangerbox.com/home.html), GeneMANIA (http://genemania.org/), STRING (h ttps://string-db.org/), GPS-Prot (http://gpsprot.org/), UniProt (https://www.uniprot.org/) and HDOCK (http://hdock.phys.hust.edu.cn/).
Declarations
Competing interests
The authors declare no competing interests.
Ethical approval and consent to participate
The Ethics Committee of the Affiliated Hospital of Guizhou Medical University approved all the experiments. All the patients had signed informed consents. We confirm that all methods were performed in accordance with the relevant guidelines and regulations. Animal studies were reported according to the ARRIVE guidelines.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Song Chen, Xue Luo and Wentai Wang contributed equally to this work.
Contributor Information
Qing-jun Gao, Email: 332495087@qq.com.
Dai-wei Zhao, Email: zzhaodaiwei@hotmail.com.
References
- 1.Boucai, L., Zafereo, M. & Cabanillas, M. E. Thyroid cancer. Rev. JAMA331(5), 425–435. 10.1001/jama.2023.26348 (2024). [DOI] [PubMed] [Google Scholar]
- 2.Coca-Pelaz, A. et al. Papillary thyroid cancer-aggressive variants and impact on management: a narrative review. Adv. Ther.37 (7), 3112–3128. 10.1007/s12325-020-01391-1 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cabanillas, M. E., Ryder, M. & Jimenez, C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr. Rev.40 (6), 1573–1604. 10.1210/er.2019-00007 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Haugen, B. R. et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer. Thyroid26 (1), 1–133. 10.1089/thy.2015.0020 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Blanchard, A., Ohanian, V. & Critchley, D. The structure and function of alpha-actinin. J. Muscle Res. Cell. Motil.10 (4), 280–289. 10.1007/BF01758424 (1989). [DOI] [PubMed] [Google Scholar]
- 6.Murphy, A. C. & Young, P. W. The actinin family of actin cross-linking proteins—A genetic perspective. Cell. Biosci.5, 49. 10.1186/s13578-015-0029-7 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Foley, K. S. & Young, P. W. The non-muscle functions of actinins: an update. Biochem. J.459 (1), 1–13. 10.1042/BJ20131511 (2014). [DOI] [PubMed] [Google Scholar]
- 8.Shao, H., Wang, J. H., Pollak, M. R. & Wells, A. α-actinin-4 is essential for maintaining the spreading, motility and contractility of fibroblasts. PLoS ONE5 (11), e13921. 10.1371/journal.pone.0013921 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Anaka, N. et al. Histological growth pattern of alpha-actinin-4 expression in thyroid cancer. Anticancer Res.34 (6), 3157–3163 (2014). [PubMed] [Google Scholar]
- 10.Wang, X. et al. The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC. Mol. Cancer20 (1), 91. 10.1186/s12943-021-01383-x (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jung, J., Kim, S., An, H. T. & Ko, J. α-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer. Carcinogenesis41 (7), 940–949. 10.1093/carcin/bgz168 (2020). [DOI] [PubMed] [Google Scholar]
- 12.Liu, P. et al. The deubiquitinating enzyme MINDY2 promotes pancreatic cancer proliferation and metastasis by stabilizing ACTN4 expression and activating the PI3K/AKT/mTOR signaling pathway. Front. Oncol.13, 1169833. 10.3389/fonc.2023.1169833 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cui, L., Lu, Y., Zheng, J., Guo, B. & Zhao, X. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK. J. Exp. Clin. Cancer Res.42 (1), 335. 10.1186/s13046-023-02904-w (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Inayatullah, M. et al. Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer. EMBO Mol. Med.16 (4), 823–853. 10.1038/s44321-024-00050-0 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kovac, B., Mäkelä, T. P. & Vallenius, T. Increased α-actinin-1 destabilizes e-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer. PLoS ONE13 (5), e0196986. 10.1371/journal.pone.0196986 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Cao, Y. et al. Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis. Pharmacol. Res.159, 104981. 10.1016/j.phrs.2020.104981 (2020). [DOI] [PubMed] [Google Scholar]
- 17.Bartha, Á. & Győrffy, B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int. J. Mol. Sci.22 (5), 2622. 10.3390/ijms22052622 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Stelzer, G. et al. The GeneCards suite: from gene data mining to disease genome sequence analysis. Curr. Protoc. Bioinform.54, 30–33. 10.1002/cpbi.5 (2016). [DOI] [PubMed]
- 19.Chandrashekar, D. S. et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia19 (8), 649–658. 10.1016/j.neo.2017.05.002 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Koch, A., Jeschke, J., Van Criekinge, W., van Engeland, M. & De Meyer, T. MEXPRESS update 2019. Nucleic Acids Res.47 (W1), W561–W565. 10.1093/nar/gkz445 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lánczky, A. & Győrffy, B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J. Med. Internet Res.23 (7), e27633. 10.2196/27633 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Vasaikar, S. V., Straub, P., Wang, J., Zhang, B. & Linkedomics Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res.46 (D1), D956–D963. 10.1093/nar/gkx1090 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Li, T. et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res.77 (21), e108–e110. 10.1158/0008-5472.CAN-17-0307 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ru, B. et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics35 (20), 4200–4202. 10.1093/bioinformatics/btz210 (2019). [DOI] [PubMed] [Google Scholar]
- 25.Shen, W. et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta1 (3), e36. 10.1002/imt2.36 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Franz, M. et al. GeneMANIA update 2018. Nucleic Acids Res.46 (W1), W60–W64. 10.1093/nar/gky311 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res.51 (D1), D638–D646. 10.1093/nar/gkac1000 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Fahey, M. E. et al. GPS-Prot: a web-based visualization platform for integrating host-pathogen interaction data. BMC Bioinform.12, 298. 10.1186/1471-2105-12-298 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.UniProt Consortium. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res.51 (D1), D523–D531. 10.1093/nar/gkac1052 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yan, Y., Zhang, D., Zhou, P., Li, B. & Huang, S. Y. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res.45 (W1), W365–W373. 10.1093/nar/gkx407 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Pan, Z. et al. IL2RA+VSIG4+ tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer. Biochim. Biophys. Acta Mol. Basis Dis.1869 (1), 166591. 10.1016/j.bbadis.2022.166591 (2023). [DOI] [PubMed] [Google Scholar]
- 32.Nicolson, N. G., Brown, T. C., Korah, R. & Carling, T. Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis. Surgery167 (1), 66–72. 10.1016/j.surg.2019.02.024 (2020). [DOI] [PubMed] [Google Scholar]
- 33.Nikiforov, Y. E. & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol.7 (10), 569–580. 10.1038/nrendo.2011.142 (2011). [DOI] [PubMed] [Google Scholar]
- 34.Huang, Y., Hong, W. & Wei, X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J. Hematol. Oncol.15 (1), 129. 10.1186/s13045-022-01347-8 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71 (3), 209–249. 10.3322/caac.21660 (2021). [DOI] [PubMed] [Google Scholar]
- 36.Tao, Y., Li, P., Feng, C. & Cao, Y. New insights into immune cells and immunotherapy for thyroid cancer. Immunol. Investig.52 (8), 1039–1064. 10.1080/08820139.2023.2268656 (2023). [DOI] [PubMed] [Google Scholar]
- 37.Jiang, Y., Yang, M., Wang, S., Li, X. & Sun, Y. Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun. (Lond.)40 (4), 154–166. 10.1002/cac2.12012 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell41 (3), 374–403. 10.1016/j.ccell.2023.02.016 (2023). [DOI] [PubMed] [Google Scholar]
- 39.Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer20 (1), 131. 10.1186/s12943-021-01428-1 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res.38 (1), 255. 10.1186/s13046-019-1259-z (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Iyer, P. C. et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J. Immunother. Cancer6 (1), 68. 10.1186/s40425-018-0378-y (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Angell, T. E. et al. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid24 (9), 1385–1393. 10.1089/thy.2014.0134 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Xie, G. F. et al. High ACTN1 is associated with poor prognosis, and ACTN1 silencing suppresses cell proliferation and metastasis in oral squamous cell carcinoma. Drug Des. Dev. Ther.14, 1717–1727. 10.2147/DDDT.S244516 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell186 (8), 1564–1579. 10.1016/j.cell.2023.03.003 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Gu, Q. Y. et al. LLGL2 inhibits ovarian cancer metastasis by regulating cytoskeleton remodeling via ACTN1. Cancers (Basel)15 (24), 5880. 10.3390/cancers15245880 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Pastushenko, I. & Blanpain, C. EMT transition states during tumor progression and metastasis. Trends Cell Biol.29 (3), 212–226. 10.1016/j.tcb.2018.12.001 (2019). [DOI] [PubMed] [Google Scholar]
- 47.Zhang, S. et al. α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3β/β-catenin pathway. Bioengineered12 (1), 5688–5704. 10.1080/21655979.2021 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Glaviano, A. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer22 (1), 138. 10.1186/s12943-023-01827-6 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request. For more information or to request data, please contact the author at zzhaodaiwei@hotmail.com. The datasets used for the bioinformatics analysis in this study are public and can be found in the following databases: The Cancer Genome Atlas (https://cancergenome.nih.gov), Genotype Tissue Expression Database (https://commonfund.nih.gov/GTEx/data), Human Protein Atlas (https://www.proteinatlas.org/), tnmplot (https://tnmplot.com/analysis/), GeneCards (https://www.genecards.org/), UALCAN (http://ualcan.path.uab.edu/analysis.html), MEXPRESS (https://www.mexpress.be/index.html), Kaplan-Meier (https://kmplot.com/analysis/index), LinkedOmics (http://www.linkedomics.org/login.php), TIMER (http://timer.cistrome.org/), TISIDB (http://cis.hku.hk/TISIDB/index.php), SangerBox (http://vip.sangerbox.com/home.html), GeneMANIA (http://genemania.org/), STRING (h ttps://string-db.org/), GPS-Prot (http://gpsprot.org/), UniProt (https://www.uniprot.org/) and HDOCK (http://hdock.phys.hust.edu.cn/).










